Oryzon Genomics S.A. (0RDB.L) LSE
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Oryzon Genomics S.A.
Address
Sant Ferran 74
Cornellà de Llobregat, 08940
Spain
Phone
34 93 515 13 13
Website
Sector
Healthcare
Industry
Biotechnology
Employees
47
First IPO Date
December 15, 2016
Key Executives
| Name | Title | Pay | Year Born |
| Carlos Manuel Buesa Arjol | Co-Founder, Chairman, Chief Executive Officer & President | 539,000 | N/A |
| Xavier Perpinya Ribera | Head of Internal Audit & Compliance | 0 | N/A |
| Neus Virgili Bernado | Director of Industrial Property | 0 | N/A |
| Sonia Paloma Gutierrez Bezon | Director of Clinical Operations | 0 | N/A |
| Rolando Gutierrez-Esteinou | Chief Medical Officer for CNS Programs | 0 | 1962 |
| Augusto Pinel Rubio | Secretary | 0 | N/A |
| Emili Torrell Cortada | Director of Business Development | 0 | N/A |
| Enric Rello Condomines | Chief Operating Officer & Chief Financial Officer | 0 | N/A |
| Jordi Xaus Pey | Scientific Director | 0 | N/A |
Description
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of epigenetics-based therapies. Its primary focus is on treating cancer and central nervous system (CNS) disorders. The company's pipeline features two lead compounds in Phase II clinical trials: iadademstat (ORY-1001), a selective LSD1 inhibitor targeting oncology, and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for CNS applications, addressing neurological and psychiatric conditions. Furthermore, ORY-3001, another LSD1 inhibitor, is currently in preclinical development for a range of non-cancer-related illnesses. Founded in 2000, Oryzon Genomics S.A. is headquartered in Cornellà de Llobregat, Spain.
